UB Therapeutics
Therapy for the Treatment of Multiple Myeloma
Company Overview
Snapshot
Founded in January 2023 by Ashraf Brik, UB Therapeutics operates with 1-10 employees. The company has secured funding across one round from two investors, including NGT HealthCare II and Israel Innovation Authority. In February 2023, UB Therapeutics raised $415,415 in Pre-Seed funding.
Business overview
UB Therapeutics is a biotechnology company focused on developing a novel therapy for multiple myeloma. The company's core technology involves cyclic peptides designed to block deubiquitinases and the proteasome, inducing apoptosis in vitro and attenuating tumor growth in vivo. These peptides aim to impair the recognition and subsequent proteasomal degradation of ubiquitinylated proteins, offering a distinct mechanism compared to existing small molecule proteasome inhibitors. UB Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development markets.
Strategic signal
In February 2023, UB Therapeutics secured $415,415 in Pre-Seed funding from NGT HealthCare II and Israel Innovation Authority. This investment validates the potential of the company's novel cyclic peptide compound for treating multiple myeloma, signaling investor confidence in its unique approach to inhibiting proteasome activity by binding to ubiquitin. The funding is earmarked for developing a stable formulation, planning regulatory pathways, and advancing R&D, indicating a clear trajectory towards human trials and market entry for a critical cancer therapy.
Log in to access full profile ›Company Intelligence Q&A
- What is UB Therapeutics' core focus?
- UB Therapeutics is focused on developing a novel therapy for the treatment of multiple myeloma, utilizing a compound based on cyclic peptides.
- When was UB Therapeutics founded?
- UB Therapeutics was founded in January 2023.
- Who is a founder of UB Therapeutics?
- Ashraf Brik is a founder of UB Therapeutics.
- What was a key funding event for UB Therapeutics?
- In February 2023, UB Therapeutics raised $415,415 in Pre-Seed funding from NGT HealthCare II and Israel Innovation Authority.
- What is the mechanism of action for UB Therapeutics' compound?
- The company's cyclic peptide compound blocks the action of deubiquitinases and the proteasome, inducing apoptosis in vitro and attenuating tumor growth in vivo, by impairing the recognition and subsequent proteasomal degradation of ubiquitinylated proteins.